Navigation Links
Developing 'second skin' military fabric to repel chemical and biological agents
Date:11/27/2012
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Developing 'second skin' military  fabric to repel chemical and biological agents
(Date:5/19/2015)... 2015 Fingerprint Cards (FPC) has received ... FPC1155 and FPC1035 from one if its module partners. Deliveries ... Q3 2015 and the sensors will be used by smartphone ... for 2015 hereby amount to 740 MSEK to date. In ... MSEK and a number of smaller orders not separately communicated ...
(Date:5/14/2015)... 14, 2015  Verificient Technologies, Inc., a ... online remote proctoring, announced a new alliance ... and creator of the Canvas Learning Management ... companies will benefit from the seamless integration ... As a fully integrated multifactor biometrics behavioral ...
(Date:5/8/2015)... Calif. , May 8, 2015 Synaptics Inc. ... solutions, today announced that members of the executive management team ... Morgan 43rd Annual Technology, Media and Telecom Conference Date: ... Hotel in Boston, MA ... 27, 2015 Time: 2:45pm ET Location: The New York Palace ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Synaptics to Present at Upcoming Investor Conferences 2
... consume foods purchased in vending machines are more likely to ... with being overweight, obese or at risk for chronic health ... research from the University of Michigan Medical School. The ... bars and other related sales that compete with USDA lunch ...
... PASADENA, Calif.Researchers at the California Institute of Technology ... carbon just one atom thickto visualize the structure of ... first direct images of how water coats surfaces at ... potentially unlimited number of other molecules, including antibodies and ...
... A new study from the Center for Interdisciplinary Chronobiological ... additional link between Light At Night (LAN) and cancer. ... out at the University of Haifa that also established ... ,environmental light pollution, which the study has shown is ...
Cached Biology News:Children who eat vended snack foods face chronic health problems, poor diet 2Caltech chemists develop simple technique to visualize atomic-scale structures 2Caltech chemists develop simple technique to visualize atomic-scale structures 3Connection between light at night and cancer revealed in additional study 2
(Date:5/27/2015)... 2015 Expanding in a big way ... Avalon Biomed Inc. recently inked a deal with ... Co. Ltd. , the largest endodontic distributor in Japan. ... market for Avalon Biomed, which manufactures Grey MTA Plus® ... dental cements that have won renown from dentists around ...
(Date:5/27/2015)... Cambridge, MA (PRWEB) May 27, 2015 ... it is directing, via its wholly owned subsidiary, ... a potential treatment for ALS that targets the innate ... the ALS Therapy Development Institute received from the 2014 ... Challenge.” The entire sum of $4 million raised directly ...
(Date:5/27/2015)... 2015  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO ) ... therapies for cancer, announced today that Dr. Marnix ... will be making an Industry Expert Theater Presentation at ... on Saturday, May 30, 2015, from 3 ... in McCormick Place. Dr. Bosch will provide ...
(Date:5/27/2015)... , May 27, 2015  US-Australian drug discovery and development ... today that it will present at the Brain Tumor Biotech ... on May 29, 2015. The venue is the Lennox ... . The Brain Tumor Biotech Summit ... pharmaceutical industry and the investment community to promote innovative new ...
Breaking Biology Technology:Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 2Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 3Ice Bucket Challenge Advances Antibody Toward Clinical Trial for ALS 2Ice Bucket Challenge Advances Antibody Toward Clinical Trial for ALS 3NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 2NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 3Novogen to Present at Brain Tumor Biotech Summit 2015 2Novogen to Present at Brain Tumor Biotech Summit 2015 3Novogen to Present at Brain Tumor Biotech Summit 2015 4Novogen to Present at Brain Tumor Biotech Summit 2015 5
... 28 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ... (NASDAQ: ATHX) announced positive results from its phase ... therapy product, administered to individuals following acute myocardial ... heart attack. The study results, which represent at ...
... CLEVELAND, Ohio , ... leading provider of medical education and simulation training,products for ... the company,s continued global expansion. Simbionix has increased,the size ... of its Corporate,Headquarters in Cleveland, OH , and ...
... Researchers have discovered mechanisms critical to interactions between hot ... fusion reactor, part of work aimed at developing coatings ... Fusion powers the stars and could lead to ... plant would produce 10 times more energy than a ...
Cached Biology Technology:Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 2Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 3Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 4Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 5Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 6Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 7Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 8Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 9Simbionix Continues its Global Expansion 2Findings show promise for nuclear fusion test reactors 2Findings show promise for nuclear fusion test reactors 3